Phase I trial of bruceantin

M. B. Garnick, R. H. Blum, G. P. Canellos, R. J. Mayer, L. Parker, A. T. Skarin, F. P. Li, I. C. Henderson, E. Frei IIIrd

Research output: Contribution to journalArticlepeer-review

14 Scopus citations

Abstract

Bruceantin was administered to 33 patients with advanced solid tumors or hematologic neoplasms. The schedule consisted of four weekly iv injections at one dose level followed by a 2-week 'no-treatment' period; this program was repeated every 6 weeks. A total of 156 weekly injections were given over a dose range of 0.8-8.5 mg/m 2. Systolic and diastolic hypotension was dose related and dose limiting at doses of ≥ 6.0 mg/m 2. Transient febrile reactions were dose-related. Gastrointestinal toxicity was commonly observed but not was not dose-limiting. There was no hematologic or renal toxicity; hepatic toxicity was subclinical and reversible. Of 18 patients evaluable for antitumor response one patient with adenocarcinoma of the cervix experienced a < 50% disease regression lasting 10 months and one patient with pleural mesothelioma experienced disease stabilization lasting 4 months. A phase II study of bruceantin is recommended at a starting dose of 5.5 mg/m 2 weekly for 4 weeks as a 4-hour iv infusion repeated at 6-week intervals.

Original languageEnglish
Pages (from-to)1929-1932
Number of pages4
JournalCancer Treatment Reports
Volume63
Issue number11-12
StatePublished - 1979
Externally publishedYes

Fingerprint

Dive into the research topics of 'Phase I trial of bruceantin'. Together they form a unique fingerprint.

Cite this